Fundraising FoxCentrose
Madison, US · Wisconsin LLC
Find your way into Centrose
Sign up to see every warm intro you have to Centrose
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Centrose team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Centrose develops Extracellular Drug Conjugates (EDCs), a class of antibody drug conjugate that targets the cell surfaceome by binding multiple extracellular proteins without internalization, for treating cancers such as metastatic cancers and lymphomas. Its pipeline includes EDCs aimed at drug-resistant non-Hodgkin lymphoma, metastatic cancers, and other lymphoma types.
Founders & leadership
JP
James PrudentFounder
JS
Jon S. ThorsonNamed on SEC filing
Board
HL
Hayden LeasonBoard director
RS
Raymond SchinaziBoard director
TW
Troy WilsonBoard director
Reported raises · per SEC filings
Form D private placements$1.9M disclosed across 4 rounds · 2014–2019
▶$100KraisedSep 2019 · 1 investors · PharmaceuticalsRule 506(b)
▶$100KraisedSep 2019 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- James PrudentExecutive Officer, Director, Promoter
- Jon S. ThorsonDirector
- Offering amount
- $200K
- Amount sold
- $100K
- First sale
- Sep 2019
- Incorporated
- Limited Liability Company, Wisconsin
- Federal exemptions
- 06b
▶$200KraisedAug 2017 · 1 investors · PharmaceuticalsRule 506(b)
▶$200KraisedAug 2017 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Jon S. ThorsonDirector
- James PrudentExecutive Officer, Director, Promoter
- Offering amount
- $1M
- Amount sold
- $200K
- Proceeds to insiders
- $210K
- First sale
- Aug 2017
- Incorporated
- Limited Liability Company, Wisconsin
- Federal exemptions
- 06b
▶$1.4MraisedJan 2016 · 3 investors · PharmaceuticalsRule 506(b)
▶$1.4MraisedJan 2016 · 3 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- James PrudentExecutive Officer, Director, Promoter
- Jon S. ThorsonDirector, Promoter
- Hayden LeasonDirector
- Raymond SchinaziDirector
- Offering amount
- $21M
- Amount sold
- $1.4M
- Minimum investment
- $50K
- Proceeds to insiders
- $1.5M
- First sale
- Jan 2015
- Incorporated
- Limited Liability Company, Wisconsin
- Federal exemptions
- 06b
▶$100KraisedJan 2014 · 1 investors · PharmaceuticalsRule 506(b)
▶$100KraisedJan 2014 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- James PrudentExecutive Officer, Director, Promoter
- Troy WilsonDirector
- Raymond SchinaziDirector
- Jon S. ThorsonDirector, Promoter
- Hayden LeasonDirector
- Offering amount
- $100K
- Amount sold
- $100K
- Minimum investment
- $100K
- First sale
- Jan 2014
- Incorporated
- Limited Liability Company, Wisconsin
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 4
Greenlight GuruGreenlight Guru provides quality management, product development, and clinical evidence software built specifically for medical device companies. Its platform helps medtech teams manage compliance, design controls, risk, and clinical data collection across the product lifecycle.
Within3Enabling virtual collaboration for life sciences on any device, anywhere, anytime
MoxsoMoxso provides phishing simulation and security awareness training for employees. The platform integrates simulated phishing emails and bite-sized training into daily workflows while monitoring for credential breaches and adapting content based on individual risk levels.
MedidataMedidata is a clinical trial software platform that serves pharmaceutical, biotech, and healthcare organizations conducting clinical research. It provides end-to-end trial management, patient data analytics, and regulatory compliance solutions across thousands of trials and millions of patients globally.
Companies working in the same space as Centrose.
Non-dilutive funding · 8 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2014 | $224.7K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2011 | $199.1K |
| National Science Foundation | Phase I | 2011 | $150K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2009 | $277.3K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2008 | $198.8K |
| National Science Foundation | Phase ISTTR | 2008 | $75K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2007 | $244.1K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2007 | $163.2K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Centrose do?
- Centrose develops Extracellular Drug Conjugates (EDCs), a class of antibody drug conjugate that targets the cell surfaceome by binding multiple extracellular proteins without internalization, for treating cancers such as metastatic cancers and lymphomas. Its pipeline includes EDCs aimed at drug-resistant non-Hodgkin lymphoma, metastatic cancers, and other lymphoma types.
- Who founded Centrose?
- Centrose was founded by James Prudent.
- How much funding has Centrose raised?
- Centrose has disclosed $1.9M raised across 4 rounds.
- Where is Centrose headquartered?
- Centrose is headquartered in Madison, US.